Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Whelan, J. S.
Right arrow Articles by Cassoni, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whelan, J. S.
Right arrow Articles by Cassoni, A. M.
Related Collections
Right arrow 2002 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:23-30, 2002
© 2002 European Society for Medical Oncology

A systematic review of the role of pulmonary irradiation in the management of primary bone tumours

J. S. Whelan1,+, R. J. Burcombe2, J. Janinis1, A. M. Baldelli3 and A. M. Cassoni1

1The Meyerstein Institute of Oncology, The Middlesex Hospital, London; 2Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK; 3Oncologica Clinica, Ospedale Regionale, Torrette di Ancona, Italy

Received 15 January 2001; revised 14 September 2001; accepted 17 September 2001.

Introduction

Adjuvant therapy in osteosarcoma (OS) and Ewing’s sarcoma (ES) is primarily directed towards treatment of subclinical lung disease. Before the advent of modern intensive chemotherapy, lung irradiation was the only available adjuvant treatment. It has proven biological activity and low morbidity. There is, however, a wide variation in its application between centres. This systematic review aims to define the evidence to support the use of lung irradiation in these diseases.

Design

A review of trials published between 1966 and 2000 was undertaken to determine the evidence for the use of pulmonary irradiation in OS and ES.

Results

Several small series of prophylactic lung irradiation (PLI) have been reported, most from over 20 years ago. These studies support the theoretical basis for the use of PLI in both OS and ES. Few randomised studies have been performed which include PLI. In OS, studies demonstrated a trend in favour of PLI compared with no adjuvant treatment and, subsequently, a level of benefit similar to that achieved with chemotherapy, but no additive effect. No studies have used PLI in addition to current standard chemotherapy regimens, or evaluated its use after successful metastatectomy. In ES, only one randomised study has addressed the role of PLI, in a comparison with vincristine, actinomycin D and cyclophosphamide combination chemotherapy with or without doxorubicin. Prolonged follow-up favoured four-drug chemotherapy. Retrospective reports from large cooperative groups suggest that the addition of whole-lung radiotherapy (WLRT) improves outcome in ES patients presenting with pulmonary metastases. However, there are no randomised study data to support this.

Conclusions

Further randomised studies are necessary to clarify the role of PLI in addition to current standard chemotherapy regimens, or its use after successful metastasectomy in patients with OS. In patients with localised ES adjuvant chemotherapy appears to be superior to PLI alone, while there is little evidence to support treatment with WLRT in patients who present with pulmonary metastases.

Key words: Ewing’s sarcoma, osteosarcoma, pulmonary irradiation, pulmonary metastases


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
H. Hjalgrim, K. Ekstrom-Smedby, K. Rostgaard, R.-M. Amini, D. Molin, S. Hamilton-Dutoit, C. Schollkopf, E. T. Chang, E. Ralfkiaer, H.-O. Adami, et al.
Cigarette Smoking and Risk of Hodgkin Lymphoma: A Population-Based Case-Control Study
Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1561 - 1566.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Hjalgrim, K. Ekstrom Smedby, K. Rostgaard, D. Molin, S. Hamilton-Dutoit, E. T. Chang, E. Ralfkiaer, C. Sundstrom, H.-O. Adami, B. Glimelius, et al.
Infectious Mononucleosis, Childhood Social Environment, and Risk of Hodgkin Lymphoma
Cancer Res., March 1, 2007; 67(5): 2382 - 2388.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Bernstein, H. Kovar, M. Paulussen, R. L. Randall, A. Schuck, L. A. Teot, and H. Juergensg
Ewing's Sarcoma Family of Tumors: Current Management.
Oncologist, May 1, 2006; 11(5): 503 - 519.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. F. Jarrett, G. L. Stark, J. White, B. Angus, F. E. Alexander, A. S. Krajewski, J. Freeland, G. M. Taylor, P. R. A. Taylor, and for the Scotland and Newcastle Epidemiology of Hod
Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study
Blood, October 1, 2005; 106(7): 2444 - 2451.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.